A Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Clinical Trial in Patients With Advanced Non-squamous Non-small Cell Lung Cancer Treated With Fruquintinib

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Clinical Trial in Patients With Advanced Non-squamous Non-small Cell Lung Cancer Treated With Fruquintinib

Recruiting
Phase of Trial: Phase III

Latest Information Update: 31 Jul 2017

At a glance

  • Drugs Fruquintinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms FALUCA
  • Sponsors Chi-Med; Hutchison MediPharma
  • Most Recent Events

    • 31 Jul 2017 According to a Chi-Med media release company expects to complete FALUCA enrollment in early 2018 and and top-line data expected in late 2018.
    • 03 Mar 2017 Topline results from the FALUCA study are expected to be released in early 2018, according to a Hutchison MediPharma media release.
    • 02 Aug 2016 According to a Chi-Med media release, company expects to complete FALUCA enrollment in early 2017 and reach overall survival endpoint maturity in late 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top